Aurora Rebuts Curaleaf's Hostile Bid Claims, Reveals UK Acquisitions and German Market Strength
ACB sits 53% above its 52-week low of $2.56.
Summary
Aurora Cannabis rebutted Curaleaf's hostile bid claims, revealing new UK acquisitions and German market data that support its defense against the US$4.00 per share takeover offer.
Key Events · M&A and Partnerships · ACB
-
Aurora Rebuts Curaleaf's Hostile Bid Claims
Aurora's Board and Special Committee are reviewing Curaleaf's US$4.00 per share unsolicited takeover bid and advise shareholders to take no action. The offer remains open for at least 105 days.
-
UK Acquisitions Expand Direct Distribution
On August 19, 2026, Aurora acquired Internode Pharma Limited and HAP Pharma Limited, expanding direct distribution in the UK — Europe's fastest-growing medical cannabis market.
-
German Market Strength Refutes Curaleaf Claims
Aurora states the German reimbursement market segment accounted for less than 10% of total German volume prior to regulatory changes, contradicting Curaleaf's characterization of a major challenge.
-
EU-GMP Capacity Up 40%+ Over Five Years
Aurora has increased EU-GMP production capacity by more than 40% over the past five years and continues to invest, including capacity added through the Safari Flower Company transaction.
Analysis · ACB · Life Sciences
Aurora Cannabis is fighting back against Curaleaf's US$4.00 per share hostile takeover bid by correcting what it calls inaccurate statements about its business. The company disclosed new material facts: it acquired two UK distributors (Internode Pharma and HAP Pharma) on August 19, expanding direct distribution in Europe's fastest-growing medical market, and revealed that German reimbursement changes affect less than 10% of its German volume. Aurora also highlighted a 40%+ increase in EU-GMP production capacity over five years and its #1 market share in Poland. These disclosures strengthen Aurora's defense narrative that Curaleaf is trying to acquire its global infrastructure at the lowest possible price. Shareholders are advised to take no action while the Special Committee reviews the offer, which remains open for at least 105 days.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $3.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $255.6M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.